Gmax Announces Approval of GMA102 for Investigational New Drug (IND) i

GMA102 has been approved by Center for Drug Evaluation (CDE, CFDA) for the IND of type 2 diabetes (T2D).

Gmax Biopharm closes the A round financing

December 28，2014, Gmax Biopharm closes the A round financing with 43 million RMB. The raised capital is mainly for moving forward the pipeline products to clinical trials.

CDE accepted GMA204 IND registration and started on-site inspection

October 29, 2015, the IND registration of GMA204 was accepted by CDE, and an on-site inspection is about to start.

GMA102 started phase 1 clinical trial in Australia

April 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia.

GMA102 IND registration accepted by CDE

September 30, 2016, CDE has accepted the IND registration of GMA 102.